secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2022-06-17T23:59:59+00:00
Accession:  0001493152-22-017017
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte Biotechnology appoints Dr. René Bernards as independent director
----------------------------------------------------------------------

- Dr. René Bernards appointed to board; he is a leader in molecular carcinogenesis at Netherlands Cancer Institute.
- Co-founded four biotech companies; member of Royal Netherlands Academy of Sciences, AACR Fellow.
- Presented new data at AACR on effectiveness of lead compound LB-100 with various anti-cancer agents.
- Compensation: one-time $100k cash fee and annual $40k payable quarterly in lieu of stock options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315222017017/0001493152-22-017017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315222017017/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-017017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer